Ubiquinol (Reduced COQ10) for Patients With Sepsis
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study aims to determine if Ubiquinol (reduced form of COQ10) will attenuate
mitochondrial injury and decrease inflammatory response in patients suffering from sepsis.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Kaneka Medical America LLC Kaneka Pharma America LLC